FDA Consum. 2004 Jul-Aug;38(4):36-7.
Pharmaceutical manufacturer Warner-Lambert has agreed to plead guilty and pay more then $430 million to resolve criminal charges and civil liabilities in connection with its Parke-Davis division's illegal and fraudulent promotion of unapproved uses for the drug Neurontin (gabapentin). The drug was approved by the Food and Drug Administration in December 1993 solely for use with other drugs to control seizures in people with epilepsy.
制药商华纳-兰伯特公司已同意认罪,并支付超过4.3亿美元,以解决与旗下帕克-戴维斯部门非法和欺诈性推广未获批的加巴喷丁(商品名:Neurontin)用药用途相关的刑事指控和民事责任。该药物于1993年12月仅被美国食品药品监督管理局批准与其他药物联合使用,用于控制癫痫患者的癫痫发作。